Antiretroviral drugs to prevent mother-to-child transmission of HIV during breastfeeding

Current HIV Research

Volumn 11, Issue 2, 2013, Pages 102-125

  Shetty, Avinash K ^a   Maldonado, Yvonne ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral prophylaxis; Breastfeeding; HIV; Infant; Maternal; PMTCT

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BREAST EPITHELIUM; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTRAPARTUM CARE; META ANALYSIS (TOPIC); MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PREGNANCY; PROPHYLAXIS; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK FACTOR; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTESTINAL MUCOSA; MALE; MASTITIS; MATERNAL-CHILD HEALTH CENTERS; MILK, HUMAN; MOTHERS; MOUTH MUCOSA; PALATINE TONSIL; POST-EXPOSURE PROPHYLAXIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 84875846031     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X11311020004     Document Type: Article

References (252)

1. Ziegler J, Cooper D, Johnson R, Gold J. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet 1985; 8434: 896-8.
2. Bedri A, Gudetta B, Isehak A, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372: 300-13.
3. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359: 119-29.
4. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, doubleblind, placebo-controlled trial. Lancet 2012; 379: 221-8.
5. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362: 2271-81.
6. The Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-tochild transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171-80.
7. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282-94.
8. Hudgens MG, Taha TE, Omer SB, et al. Pooled Individual Data Analysis of 5 Randomized Trials of Infant Nevirapine Prophylaxis to Prevent Breast-Milk HIV-1 Transmission. Clin Infect Dis 2013; 56: 131-9.
9. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; (7): CD003510.
10. Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS 2011; 25(13): 1611-8.
11. Coovadia H. Current issues in prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS 2009; 4: 319-24.
12. Mofenson LM. Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 2010; 15(4): 537-53.
13. Fowler MG, Gable AR, Lampe MA, Etima M, Owor M. Perinatal HIV and its prevention: Progress towards an HIV-free generation. Clin Perinatol 2010; 37: 699-719.
14. Panel on Treatment of HIV-infected pregnant women and prevention of perinatal transmission: Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce HIV-1 transmission. July 2012; p.1-117. Available at: http://aidsinfo.nih.gov/guidelines. Accessed October 29, 2012.
15. Cooper ER, Charurat M, Mofenson LM, et al. Combination antiretroviral strategies for treatment of pregnant HIV-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29(5): 484-94.
16. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22(8): 973-81.
17. Kourtis AP, Vincenzi I, Jamieson DJ, Bulterys M. Antiretroviral drugs during breastfeeding for the prevention of postnatal transmission of HIV. Adv Exp Med Biol 2012; 743:173-83.
18. Fowler MG, Kourtis AP, Aizire J, Onyango-Mukumbi C, Bulterys M. Breastfeeding and transmission of HIV-1: epidemiology and global magnitude. Adv Exp Med Biol 2012; 743: 3-25.
19. Bulterys M, Ellington S, Kourtis AP: HIV-1 and breastfeeding: biology of transmission and advances in prevention. Clin Perinatol 2010; 37(4): 807-24.
20. Mofenson LM. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2010; 50(Suppl 3): S130-48.
21. Read JS. Prevention of mother-to-child transmission of HIV: antiretroviral strategies. Clin Perinatol 2010; 37(4): 765-76.
22. McIntyre J. Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries. Curr Opin HIV AIDS 2010; 5: 48-53.
23. Taha TE. Mother-to-child transmission of HIV-1 in sub-Saharan Africa: past, present and future challenges. Life Sci 2011; 88: 917-21.
24. Buchanan AM, Cunningham CK. Advances and failures in preventing perinatal human immunodeficiency virus infection. Clin Microbiol Rev 2009; 22(3): 493-507.
25. Joint United Nations Program on HIV/AIDS (UNAIDS). Together we will end AIDS. Geneva, Switzerland; UNAIDS; 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/e pidemiology/20122/20120718_togetherwewillendaids_en.pdf. Acce-ssed November 27, 2012.
26. Becquet R, Dabis F. Turning the tide on HIV in women and children: preventing breast-milk HIV transmission while increasing maternal life expectancy. Clin Infect Dis 2012; 56: 140-2.
27. Young SL, Mbuya MN, Chantry CJ, et al. Current knowledge and future research on infant feeding in the context of HIV: basic, clinical, behavioral, and programmatic perspectives. Adv Nutr 2011; 2: 225-43.
28. WHO Collaborative Study Team. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Lancet 2000; 355: 451-5.
29. Labbok MH. Effects of breastfeeding on the mother. Pediatr Clin North Am 2001; 48: 143-58.
30. Stuebe A. The risks of not breastfeeding for mothers and infants. Rev Obstet Gynecol 2009; 2: 222-31.
31. Perez A, Labbok MH, Queenan JT. Clinical study of the lactational amenorrhoea method for family planning. Lancet 1992; 339: 968-70.
32. Victora CG, Smith PG, Vaughan JP, et al. Evidence for protection by breast-feeding against infant deaths from infectious diseases in Brazil. Lancet 1987; 2: 319-22.
33. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003; 361: 2226-34.
34. Ip S, Chung M, Raman G, Trikalinos TA, Lau J. A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. Breastfeed Med 2009; 4 Suppl 1: S17-30.
35. Cournil A, De Vincenzi I, Gaillard P, et al. Relationship between mortality and feeding modality among children born to HIVinfected mothers in a research setting: The Kesho Bora Study. AIDS 2012 [Epub ahead of print].
36. Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIVInfected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2010; 53: 28-35.
37. Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53: 6-13.
38. Kagaayi J, Gray RH, Brahmbhatt H, et al. Survival of infants born to HIV-positive mothers, by feeding modality, in Rakai, Uganda. PLoS One 2008; 3: e3877.
39. Kuhn L, Aldrovandi G. Survival and health benefits of breastfeeding versus artificial feeding in infants of HIV-infected women: developing versus developed world. Clin Perinatol 2010; 37: 843-62.
40. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008; 359: 130-41.
41. Taha TE, Hoover DR, Chen S, et al. Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis 2011; 53: 388-95.
42. Taha TE, Kumwenda NI, Hoover DR, et al. The impact of breastfeeding on the health of HIV-positive mothers and their children in Sub-Saharan Africa. Bull World Health Organ 2006; 84: 546-54.
43. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana, a randomized trial: the Mashi Study. JAMA 2006; 296: 794-805.
44. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. Clin Infect Dis 2010; 50: 437-44.
45. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369: 1107-16.
46. Kuhn L, Reitz C, Abrams EJ, et al. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr 2009; 21: 83-93.
47. Chi BH, Adler MR, Bolu O, et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr 2012; 60 (Suppl 3): S78-87.
48. Spensley A, Sripipatana TS, Turner AN, et al. Preventing motherto-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience. Am J Public Health 2009; 99: 631-7.
49. Guay L. Decreasing HIV transmission through breastfeeding: moving from evidence to practice. J Acquir Immune Defic Syndr 2011; 57: 258-60.
50. Ong-ech JO, Hoffman HJ, Kose J, et al. Provision of services and care for HIV-exposed infants: a comparison of maternal and child health clinic and HIV comprehensive care clinic models. J Acquir Immune Defic Syndr 2012; 61(1): 83-9.
51. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-80.
52. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV-1 Transmission Study Group. Lancet 1999; 353: 773-80.
53. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomized trial. Lancet 1999; 353:781-5.
54. Dabis F, Msellati P, Meda N et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV-1 in breastfed children in Côte d'Ivoire and Burkina Faso: adouble-blind placebo-controlled multicentre trial. DITRAME Study Group. Lancet 1999; 353: 786-92.
55. Leroy V, Karon J, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-tochild transmission of HIV-1 in West Africa. AIDS 2002; 16: 631-41.
56. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda [Petra Study]: a randomized, double blind, placebo-controlled trial. Lancet 2002; 359:1178-86.
57. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIV-1NET 012 randomized trial. Lancet 1999; 354: 795-802.
58. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859-68.
59. Marseille E, Kahn JG, Mmiro F et al. Cost effectiveness of singledose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in Sub-Saharan Africa. Lancet 1999; 354: 803-9.
60. Mofenson LM. Prevention of mother-to-child HIV-1 transmission-why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr 2011; 58: 359-62.
61. DeCock KM, Fowler MG, Mercier E, et al. Prevention of motherto-child transmission of HIV infection in resource-poor settings. Translating research into policy and practice. JAMA 2000; 283: 1175-82.
62. Kuhn L. Sinkala M, Kankasa C, et al. High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS One 2007; 2: e1363.
63. Coutsoudis A, Dabis F, Fawzi W, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data metaanalysis. J Infect Dis 2004; 189: 2154-66.
64. Kourtis AP, Lee FK, Abrams EJ, et al. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 2006; 6: 726-32.
65. Aldrovandi GM, Kuhn L. What babies and breasts can teach us about natural protection from HIV infection. J Infect Dis 2010; 202 (S3): S366-70.
66. Bryson YJ, Luzuriaga K, Sullivan JL, et al. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327: 1246-7.
67. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283: 1167-74.
68. Mmiro FA, Aizire J, Mwatha AK, et al. Predictors of early and late mother-to-child transmission of HIV-1 in a breastfeeding population: HIV-1 network for prevention trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr 2009; 52: 32-9.
69. Koulinska IN, Villamor E, Msamanga G, et al. Risk of HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes. Virus Res 2006; 120: 191-8.
70. Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187: 741-7.
71. Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission through breastfeeding: a study in Malawi. JAMA 1999; 282: 744-9.
72. Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother to child transmission of HIV-1. AIDS 2000; 14: 2535-41.
73. Bulterys M, Chao A, Dushimimana A, Saah A. HIV-1 seroconversion after 20 months of age in a cohort of breastfed children born to HIV-1-infected women in Rwanda. AIDS 1995; 9: 93-4.
74. Van de Peere P, Rubbo PA, Viljoen J, et al. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV. Sci Transl Med 2012; 4(143): 143sr3.
75. Dunn DT, Newell M-L, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340: 585-8.
76. Jamieson DJ, Sibailly TS, Sadek R, et al. HIV-1 viral load and other risk factors for mother-to-child transmission of HIV-1 in a breast-feeding population in Côte d'Ivoire. J Acquir Immune Defic Syndr 2003; 34: 430-6.
77. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA, load, genital hIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183: 206.
78. Humphrey JH, Marinda E, Mutasa K, et al. Mother to child transmission of HIV-1 among Zimbabwean women who seroconverted postnatally: prospective cohort study. Br Med J 2010; 341: c6580.
79. Liang K, Gui X, Zhang YZ, et al. A case series of 104 women infected with HIV-1 via blood transfusion postnatally: High rate of HIV-1 transmission to infants through breast-feeding. J Infect Dis 2009; 200: 682-6.
80. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of human immunodeficiency virus type1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012 trial). J Infect Dis 2001; 184: 914-7.
81. Bjorndal A, Sonnerborg A, Tscherning C, et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS 1999; 15: 647-53.
82. Renjifo B, Gilbert P, Chaplin B, et al. Preferential in utero transmission of HIV-1 subtype C compared to subtype A or D. AIDS 2004; 18: 1629-36.
83. Yang C, Li M, Newman RD, et al. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS 2003; 11: 1667-74.
84. Koulinska IN, Villamor E, Msamanga G, et al. Risk of HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes. Virus Res 2006; 120: 191-8.
85. Slyker JA, Chung MH, Lehman DA, et al. Incidence and correlates of HIV-1 RNA detection in the breast milk of women receiving HAART for the prevention of HIV-1 transmission. PLoS One 2012; 7(1): e29777.
86. Koulinska IN, Villamor E, Chaplin B, et al. Transmission of cellfree and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr 2006; 41: 93-9.
87. Lewis P, Nduati R, Kreiss JK, et al. Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis 1998; 177: 34-9.
88. Willumsen JF, Newell ML, Filteau SM, et al. Variation in breastmilk HIV-1 viral load in left and right breasts during the first 3 months of lactation. AIDS 2001; 15: 1896-8.
89. Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS 2000; 14: 2535-41.
90. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and motherto-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180: 93-8.
91. Kumwenda N, Miotti PG, Taha TE, et al. Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in Malawi. Clin Infect Dis 2002; 35: 618-24.
92. Phiri W, Kasonka L, Collin S, et al. Factors influencing breast milk HIV-1 RNA viral load among Zambian women. AIDS Res Hum Retroviruses 2006; 22: 607-14.
93. Kupka R, Garland M, Msamanga G, et al. Selenium status, pregnancy outcomes, and mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005; 29: 201-10.
94. Mehta S, Hunter DJ, Mugusi FM, et al. Perinatal outcomes, including mother-to-child transmission of HIV-1, and child mortality and their association with maternal vitamin D status in Tanzania. J Infect Dis 2009; 200: 1022-30.
95. Semba RD, Miotti P, Chiphangwi J, et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994; 343: 1593-7.
96. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. Lancet 1999; 354: 471-6.
97. Iliff PJ, Piwoz EG, Tavengwa NV et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-1-free survival. AIDS 2005; 19: 699-708.
98. Kourtis AP, Jamieson DJ, de Vincenzi I, et al. Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. Am J Obstet Gynecol 2007; 197(Suppl 3): S113-22.
99. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach, 2010 version. Geneva, Switzerland: World Health Organization; 2010. http://www.who.int/hiv/pub/mtct/guidelines/en/. Last accessed 15 January 2013.
100. World Health Organization (2010) Guidelines on HIV-1 and infant feeding. Principles and recommendations for infant feeding in the context of HIV-1 and a summary of evidence. pp 1-49. http://whqlibdoc.who.int/publications/2010/9789241599535_eng.p df. Accessed 16 Jan 2013.
101. Bulterys PL, Dalai SC, Katzenstein DA. Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission. Clin Perinatol 2010; 37(4): 739-50.
102. MacDonald KS, Embree J, Njenga S, et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998; 177: 551-6.
103. Mackelprang RD, John-Stewart G, Carrington M, et al. Maternal HLA Homozygosity and Mother-Child HLA Concordance Increase the Risk of Vertical Transmission of HIV-1. J Infect Dis 2008; 197: 1156-61.
104. Mackelprang RD, Carrington M, John-Stewart G, et al. Maternal human leukocyte antigen A*2301 is associated with increased mother-to-child HIV-1 transmission. J Infect Dis 2010; 202: 1273-7.
105. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV-1: pathogenesis, mechanisms and pathways. Clin Perinatol 2010; 37: 721-38.
106. Kourtis AP, Butera S, Ibegbu C, Belec L, Duerr A. Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis 2003; 3: 786-93.
107. Toniolo A, Serra C, Conaldi PG, et al. Productive HIV-1 infection of normal human mammary epithelial cells. AIDS 1995; 9: 859-66.
108. Richardson BA, John-Stewart GC, Hughes JP, et al. Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis 2003; 187: 736-40.
109. Shapiro RL, Ndung'u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 2005; 192: 713-9.
110. Ndirangu J, Viljoen J, Bland RM, et al. Cell-free (RNA) and cellassociated (DNA) HIV-1 and postnatal transmission through breastfeeding. PLoS One 2012; 7(12): e51493.
111. Van De Perre P. Mother-to-child transmission of HIV-1: the "all mucosal" hypothesis as a predominant mechanism of transmission. AIDS 1999; 13: 1133-8.
112. Meng G, Wei X, Wu X, et al. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med 2002; 8: 150-6.
113. Tugizow M, Herrera R, Velupillai P, et al. Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol 2012; 86(5): 2556-70.
114. Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004; 20: 247-53.
115. Frankel SS, Tenner-Racz K, Paul Racz, et al. Active replication of HIV-1 at the lymphoepithelial surface of the tonsil. Am J Pathol 1997; 151: 89-96.
116. Malamud D, Wahl SM. The mouth: a gateway or a trap for HIV. AIDS 2009; 24: 5-16.
117. Baron S, Poast J, Richardson CJ, et al. Oral transmission of human immunodeficiency virus by infected seminal fluid and milk: a novel mechanism. J Infect Dis 2000; 181: 498-504.
118. Shugars DC. Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 1999; 179(Suppl 3): S431-5.
119. Chirico G, Marzollo R, Cortinovis S, et al. Antiinfective properties of human milk. J Nutr 2008; 138: S1801-6.
120. Lepage P, Van de Perre P. The immune system of breast milk: antimicrobial and anti-inflammatory properties. Adv Exp Med Biol 2012; 743: 121-37.
121. Kuhn L. Milk mysteries: who are women who exclusively breastfeed less likely to transmit HIV-1 during breastfeeding? Clin Infect Dis 2010; 50: 770-2.
122. Requena M, Bouhlal H, Nasreddine N, et al. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 2008; 123: 508-18.
123. Saeland E, de Jong MA, Nabatov AA, et al. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol 2009; 46: 2309-16.
124. Habte HH, de Beer C, Lotz ZE, et al. Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay. Neonatology 2008; 93: 162-70.
125. Harmsen MC, Swart PJ, de Bethune MP, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172: 380-8.
126. Swart PJ, Kuipers ME, Smit C, et al. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses 1996; 12: 769-75.
127. Groot F, Geijtenbeek TB, Sanders RW, et al. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J Virol 2005; 79: 3009-15.
128. Naarding MA, Dirac AM, Ludwig IS, et al. Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+T cells. Antimicrob Agents Chemother 2006; 50: 3367-74.
129. Stax MJ, Naarding MA, Tanck MW, et al. Binding of human milk to pathogen receptor DC-SIGN varies with bile salt stimulated lipase (BSSL) gene polymorphism. PLoS One 2011; 6: e17316.
130. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting antihuman immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 456-64.
131. Villamor E, Koulinska IN, Furtado J, et al. Long-chain n-6 polyunsaturated fatty acids in breast milk decrease the risk of HIV transmission through breastfeeding. Am J Clin Nutr 2007; 86: 682-9.
132. Bode L, Kuhn L, Kim HY, et al. Human milk oligosaccharide concentration and risk of postnatal transmission of HIV through breastfeeding. Am J Clin Nutr 2012; 96: 831-9.
133. Wahl A, Swanson MD, Nochi T, Olesen R, Denton PW, et al. Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice. PLoS Pathog 2012; 8(6): e1002732.
134. Bosire R, Guthrie BL, Lohman-Payne BL, et al. Longitudinal comparison of chemokines in breastmilk early postpartum among HIV-1 infected and uninfected Kenyan women. Breastfeeding Med 2007; 2: 129-38.
135. Hawkes JS, Bryan D-L, Gibson RA. Cytokine production by human milk cells and peripheral blood mononuclear cells from the same mothers. J Clin Immunol 2002; 22: 338-44.
136. Ichikawa M, Sugita M, Takahashi M, et al. Breast milk macrophages spontaneously produce granulocyte-macrophage colony-stimulating factor and differentiate into dendritic cells in the presence of exogenous interleukin-4 alone. Immunology 2003; 108: 189-95.
137. Becquart P, Petitjean G, Al Tabaa Y, et al. Detection of a large Tcell reservoir able to replicate HIV-1 actively in breast milk. AIDS 2006; 20: 1453-62.
138. Petitjean G, Becquart P, Tuaillon E, et al. Isolation and characterization of HIV-1-infected resting CD4R T lymphocytes in breast milk. J Clin Virol 2007; 39: 1-8.
139. Kourtis AP, Ibegbu C, Theiler R, et al. Breast milk CD4RT cells express high levels of chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy. J Infect Dis 2007; 195: 965-72.
140. Sabbaj S, Edwards BH, Ghosh MK, et al. Human immunodeficiency virus-specific CD8R T cells in human breast milk. J Virol 2002; 76: 7365-73.
141. Sabbaj S, Ghosh MK, Edwards BH, et al. Breast milk-derived antigen specific CD8R T cells: an extralymphoid effector memory cell population in humans. J Immunol 2005; 174: 2951-6.
142. Tuaillon E, Valea D, Becquart P, et al. Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. J Immunol 2009; 182:7155-62.
143. Bélec L, Kourtis AP. B lymphocyte-derived humoral immune defenses in breast milk transmission of the HIV-1. Adv Exp Med Biol 2012; 743: 139-60.
144. Sabbaj S, Ibegbu CC, Kourtis AP. Cellular immunity in breast milk: implications for postnatal transmission of HIV-1 to the infant. Adv Exp Med Biol 2012; 743: 161-9.
145. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012; 8: e1002739.
146. + T cells. Antimicrob Agents Chemother 2006; 50: 3367-74.
147. Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992; 255: 1134-7.
148. Wu X, Parast AB, Richardson BA, et al. Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant. J Virol 2006; 80: 835-44.
149. Russell ES, Kwiek JJ, Keys J, et al. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol 2011; 85: 8253-62.
150. Becquart P, Hocini H, Levy M, et al. Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis 2000; 181: 532-9.
151. Yu X, Pollock D, Duval M, Lewis C. Neutralization of HIV by Milk Expressed Antibody. J Acquir Immune Defic Syndr 2013; 62: 10-6.
152. Lohman-Payne B, Slyker JA, Moore S, et al. Breast milk cellular HIV-specific interferon-responses are associated with protection from peripartum HIV transmission. AIDS 2012; 26: 2007-16.
153. Farquhar C, Lohman-Payne B, Overbaugh J, et al. Breast milk HIV-1 RNA levels and female sex are associated with HIV-1-specific CD8+ T-cell responses in HIV-1-exposed, uninfected infants in Kenya. J Infect Dis 2011; 204: 1806-10.
154. Tiemessen CT, Sgakekogff S, Meddows-Taylor S, et al. Cutting Edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J Immunol 2009; 182: 5914-8.
155. Lopalco L. Natural anti-CCR5 antibodies in HIV-infection and exposure. J Transl Med 2011; 9(Suppl 1): S4.
156. Valea D, Tuaillon E, Al Tabaa Y, et al. CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. Retrovirology 2011; 8: 34.
157. Salazar-Gonzalez JF, Salazar MG, Learn GH, et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol 2011; 85: 2751-63.
158. Gray RR, Salemi M, Lowe A, et al. Multiple independent lineages of HIV-1 persist in breast milk and plasma. AIDS 2011; 25: 143-52.
159. Rainwater SM, Wu X, Nduati R, et al. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res 2007; 5: 189-97.
160. Kong X, West JT, Zhang H, et al. The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses. J Virol 2008; 82: 11609-18.
161. Zhang H, Rola M, West JT, et al. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 2010; 400: 164-74.
162. Roux M, McWilliams M, Phillips-Quagliata J, Weisz-Carrington P, Lamm M. Origin of IgA-secreting plasma cells in the mammary gland. J Exp Med 1977; 146: 1311-22.
163. Goldblum R, Ahlstedt S, Carlsson B, et al. Antibody-forming cells in human colostrum after oral immunisation. Nature 1975; 257: 797-8.
164. Weisz-Carrington P, Roux M, McWilliams M, PHILLIPSQuagliata J, Lamm M. Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol 1979; 123: 1705-8.
165. Fouda GG, Mahlokozera T, Salazar-Gonzalez JF, et al. Postnatallytransmitted HIV-1 Envelope variants have similar neutralizationsensitivity and function to that of nontransmitted breast milk variants. Retrovirology 2013; 10(1): 3.
166. Faraquhar C, John-Stewart G. The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression. Clin Exp Immunol 2003; 134: 367-77.
167. Walter J, Kuhn L, Aldrovandi GM. Advances in basic science understanding of mother-to-child HIV-1 transmission. Curr Opin HIV AIDS 2008; 3: 146-50.
168. Farquhar C, Rowland-Jones S, Mbori-Ngacha D, et al. Human leukocyte antigen (HLA) B*18 and protection against mother-tochild HIV type 1 transmission. AIDS Res Hum Retroviruses 2004; 20(7): 692-7.
169. Semrau K, Ghosh M, Kankasa C, et al. Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breastfeeding. J Acquir Immune Defic Syndr 2008; 47: 320-8.
170. Neville MC, Neifert MR. Lactation: Physiology, Nutrition, and Breastfeeding. Plenum Press; New York: 1983.
171. Neville MC, Allen JC, Archer PC, et al. Studies in human lactation: milk volume and nutrient composition during weaning and lactogenesis. Am J Clin Nutr 1991; 54: 81-92.
172. Gantt S, Shetty AK, Seidel KD, et al. Laboratory indicators of mastitis are not associated with elevated HIV-1 DNA loads or predictive of HIV-1 RNA loads in breast milk. J Infect Dis 2007; 196: 570-6.
173. Dorosko SM, Connor RI. MEC and endosomal uptake of HIV Primary Human Mammary Epithelial Cells Endocytose HIV-1 and Facilitate Viral Infection of CD4+ T Lymphocytes J. Virol 2010; 84: 10533-42.
174. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR. APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milkborne virions. Cell Host Microbe 2010; 8(6): 534-43.
175. Bulek K, Swaidani S, Aronica M, Li X. Epithelium: the interplay between innate and Th2 immunity. Immunol Cell Biol 2010; 88: 257-68.
176. Connor EM, Mofenson LM. Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: Pediatric AIDS Clinical Trials Group protocol 076--results and treatment recommendations. Pediatr Infect Dis J 1995; 14: 536-41.
177. Centers for Disease Control and Prevention. Achievements in public health. Reduction in perinatal transmission of HIV infection--United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006; 55: 592-7.
178. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 2005; 19: 1865-75.
179. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19: 309-18.
180. Moodley D, Coovadia H, et al. A multicenter randomized trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of HIV-1. J Infect Dis 2003; 187: 725-35.
181. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to child transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343: 982-91.
182. Bhoopat L, Khunamornpong S, Lerdsrimongkol P, et al. Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission. J Acquir Immune Defic Syndr 2005; 40: 545-50.
183. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-28.
184. Dabis F, Bequent L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19: 309-18.
185. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antrretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 12: 1281-8.
186. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288: 189-98.
187. Taha TE, Kumwenda N, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomized clinical trial. Lancet 2003; 362: 1171-7.
188. Taha TE, Kumwenda N, Hoover DR. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292: 202-9.
189. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 2005; 19: 1289-97.
190. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409-14.
191. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366: 2368-79.
192. American Academy of Pediatrics. Human immunodeficiency virus infection, in Pickering LK, ed. Red Book, 28th ed. Elk Grove Village, IL, American Academy of Pediatrics, 2012, pp 418-437.
193. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005; 38: pp. 87-95.
194. Garcia P, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type-1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341(6): 394-402.
195. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010; 50(4): 585-96.
196. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335(22): 1621-9.
197. Mofenson LM. Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis 2003; 14: 295-308.
198. Arrive E, Newell LM, Ekouevi KD, et al. Prevalence of resistance to nevirapine im mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36: 1009-21.
199. Lockman S, Shapiro LR, Smeaton ML, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356: 135-47.
200. Jourdain, Wagner AT, Ngo-Giang-Huong N, et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis 2010; 50: 1397-404.
201. Coffie AP, Ekouevi KD, Chaix LM, et al. Maternal 12-month response to antiretroviral therapy following prevention of motherto-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 2008; 46: 611-21.
202. Stringer SJ, McConnell SM, Kiarie J, et al. Effectiveness of nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirpaine: a multi-country, prospective cohort study. PLoS Med 2010; 7: e1000233.
203. Wagner AT, Kress MC, Beck I, et al. Detection of HIV-1-Drugresistance in women following single-dose-nevirapine: comparison of plasma RNA versus cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol 2010; 48: 1555-61.
204. Eshelman HS, Hoover RD, Hudelson ES, et al. Development of nevirapine in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis 2006; 193: 479-81.
205. Marazzi MC, Liotta G, Nielsen-Saines K, et al. Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life. AIDS. 2010; 24(18): 2819-26.
206. Palombi L, Marazzi MC, Voetberg A, et al. Treatment acceleration program and the experience of DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21: S65-71.
207. Marazzi C, Nielsen-Saines K, Buonomo E, et al. Increased infant HIV-1 free survival at one year of age in Sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breastfeeding. Pediatr Infect Dis J 2009; 28: 483-7.
208. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8: e1001015.
209. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-tochild transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52: 406-16.
210. Peltier CA, Ndayisaba GF, Lepage P, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother to child infection. AIDS 2009; 23: 2415-23.
211. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012; 379(9835): 2449-58.
212. Kesho Bora Study Group. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr 2010; 54: 533-41.
213. Mofenson LM. Protecting the next generation-eliminating perinatal HIV-1 infection. N Engl J Med 2010; 362: 2316-8.
214. Becquet R, Ekouevi DK. Breastfeeding, triple ARV prophylaxis, and MTCT prevention. Lancet 2011; 11: 154-5.
215. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206: 1695-705.
216. Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note of caution. J Infect Dis 2012; 206: 1639-41.
217. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8(3): e1000430.
218. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One 2009; 4(1): e4096. Available at http://www.ncbi.nlm.nih.gov/pubmed/19119321.
219. Lidstrom J, Guay L, Musoke P, et al. Multi-class drug resistance arises frequently in HIV-infected breastfeeding infants whose mothers initiate HAART postpartum. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections (CROI); February 16-19, 2010; San Francisco, CA. Abstract 920.
220. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53: 1170-6.
221. Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19: 1912-5.
222. Vyankandondera J, Luchters S, Hassink E, et al. Simba-Stopping Infection from Mother to Child via Breastfeeding in Africa. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis (Paris, France). 2003. Abstract LB07.
223. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-tochild transmission of HIV-1 through breastfeeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra study. J Acquir Immune Defic Syndr 2008; 48: 315-23.
224. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296: 794-805.
225. Omer SB, Six Week Extended-Dose Nevirapine Study Team. Twelve month follow-up of Six Week Extended-Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS 2011; 25: 767-76.
226. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment failure for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-20.
227. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: toward universal access, recommendations for a public health approach 2006 revision. Geneva, Switzerland: World Health Organization, 2006.
228. Becquet R, Dabis F. Turning the tide on HIV in women and children: preventing breast-milk HIV transmission while increasing maternal life expectancy. Clin Infect Dis 2010; DOI:10.1093/cid/cis813.
229. Kuhn L, Aldrovandi G, Sinkala M, et al. Potential impact of new World Health Organization criteria for antiretroviral treatment for prevention of mother to child HIV transmission. AIDS 2010; 24: 1374-7.
230. Brown ER, Otino P, Mbori-Ngacha DA, et al. Comparison of CD4 cell count, viral load and other markers for prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis 2009; 199: 1292-300.
231. Severe P, Pape J, Fitzgerald DW, et al. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200-350 cells/mL (CIPRAHT001). In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). 2009. Abstract H-1230.
232. Becquet R, Ekouevi DK, Arrive E, et al. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1 infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009; 49: 1936-45.
233. Chasela C, Chen YQ, Fiscus S, et al. Risk factors for late postnatal transmission of human immunodeficiency virus type 1 in Sub-Saharan Africa. Pediatr Infect Dis J 2008; 27: 251-6.
234. th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 12-22 July 2009, Capetown, South Africa. Abstract TuPEC053.
235. Hoffman RM, Black V, Technau K, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-tochild transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2010; 54: 35-41.
236. World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: executive summary, April 2012. Available at: http://www.who.int/hiv/PMTCT_update.pdf. Accessed January 12, 2013.
237. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
238. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-tochild transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378: 282-4.
239. Schouten E. Beyond Option B: discussion of B+ and other alternatives to pre-natal and neonatal prophylaxis. (Satellite session: Prevention of vertical transmission and beyond: how to identify, enroll and retain children in treatment programmes in resource-limited settings). In: 19th International AIDS Conference; 22-27 July 2012; Washington, DC. Available at: http://http://pag.aids2012.org/session.aspx?s=21#3. Accessed 15 January 2013.
240. UNICEF. A business case for Options B and B+ to eliminate mother to child transmission of HIV by 2015. July 2012. http://eptcasiapacific.org/content/business-case-options-b-and b-eliminate-mother-child-transmission-hiv-2015-model-methodology (accessed Jan 2, 2013).
241. Coutsoudis A, Gaga A, Desmond C, Barron P, Black V, Coovadia H. Is Option B+ the best choice. Lancet 2013; 381: 269-71.
242. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26: 2039-52.
243. World Health Organization. Rapid advice: infant feeding in the context of HIV-November 2009. Geneva, Switzerland: World Health Organization, 2009. http://www.who.int.go.libproxy.wfubm c.edu/hiv/pub/paediatric/rapid_advice_infant.pdf. Accessed 17 July 2012.
244. Onyango-Makumbi C, Bagenda D, Mwatha A, et al. Early weaning of HIV-1 exposed uninfected infants and risk of serious gastroenteritis: findings from two perinatal HIV-1 prevention trials in Kampala, Uganda. J Acquir Immune Defic Syndr 2010; 53: 20-7.
245. Thomas T, Masaba R, van Eijk A, et al. Rates of diarrhea associated with early weaning among infants in Kisumu, Kenya. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Boston). 2008. Abstract 774.
246. Creek TL, Kim A, Lu L, et al. Hospitalization and mortality among primarily nonbreastfed children during a large outbreak of diarrhea and malnutrition in Botswana. J Acquir Immune Defic Syndr 2010; 53: 14-9.
247. Israel-Ballard K, Donovan R, Chantry C, et al. Flash-heat inactivation of HIV-1 in human milk: a potential method to reduce postnatal transmission in developing countries. JAIDS 2007; 45: 318-23.
248. Lyons C, Mushavi A, Ngobeni-Allen F, Yule R, Abrams E. Ending pediatric AIDS and achieving a generation born HIV-free. J Acquir Immune Defic Syndr 2012; 60 Suppl 2: S35-8.
249. Karim QA, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis 2010; 50(S3): S122-9.
250. Mahy M, Stover J, Karagu K. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Trans Infect 2010; 86(Suppl 2): ii48-55.
251. Stringer EM, Ekouevi DK, Coetzee D, et al. Coverage of nevirapine-based services to prevent mother-to child HIV transmission in 4 African countries. JAMA 2010; 304: 293-302.
252. Guay L. Decreasing HIV transmission during breastfeeding: moving from evidence to practice. J Acquir Immune Defic Syndr 2011; 57: 258-60.